AstraZeneca’s COVID-19 vaccine has been estimated to have prevented 232,766 deaths in Vietnam, according to an independent assessment of vaccine effectiveness conducted by Airfinity.
AstraZeneca’s vaccine was the first COVID-19 vaccine approved by Vietnam’s Ministry of Health (MoH). With more than 72 million doses delivered to Vietnam, AstraZeneca’s COVID-19 vaccine is one of the most used in the country.
Nitin Kapoor, chairman and general director at AstraZeneca Vietnam and Asia Area Frontier Markets said, “This data reaffirms that vaccination is the fastest way to overcome the pandemic and that our vaccine is highly effective in preventing serious illness and death. AstraZeneca remains committed to collaborating closely with the Vietnamese government, the MoH, and our partners to protect people’s lives, in addition to achieving our mutual long-term goal of strengthening health system sustainability and resilience.”
|AstraZeneca’s COVID-19 vaccine
The analysis by Airfinity covers the period from December 8, 2020, to December 8, 2021. The data showed that globally, the AstraZeneca vaccine is estimated to have saved more than 6.3 million lives.
AstraZeneca’s COVID-19 vaccine was invented by the University of Oxford. The vaccine has been granted a conditional marketing authorisation or emergency use in more than 125 countries. It also has Emergency Use Listing from the World Health Organization, which accelerates the pathway to access in up to 144 countries through the COVAX Facility.
Since the pandemic began, AstraZeneca and its global partners have released more than three billion vaccine doses to more than 180 countries, and approximately two-thirds of these doses have been delivered to low and lower middle-income countries.
To provide additional protection for immunocompromised and high-risk populations against COVID-19, AstraZeneca has also developed a long-acting antibody combination that has been available in Vietnam since March, following a special import approval by the MoH. According to various studies, the antibody duo retains its neutralising activity against Omicron SARS-CoV-2 subvariants and all tested variants of concern to date.